Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2012, Article ID 712613, 8 pages
http://dx.doi.org/10.1155/2012/712613
Review Article

Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma

1Division of Medical Oncology and Hematological Malignancies Program, Duke University Medical Center, Durham, NC 27710, USA
2Division of Cellular Therapy and Hematological Malignancies Program, Duke University Medical Center, Durham, NC 27710, USA

Received 9 February 2012; Accepted 5 April 2012

Academic Editor: Antonio Palumbo

Copyright © 2012 S. A. Tuchman et al. is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Surveillance, Epidemiology, and End Results (SEER) Program and the National Center for Health Statistics, 2010, http://www.cancer.gov/aboutnci/servingpeople/snapshots/myeloma.pdf.
  2. P. G. Richardson, R. L. Schlossman, E. Weller et al., “Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma,” Blood, vol. 100, no. 9, pp. 3063–3067, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Dimopoulos, A. Spencer, M. Attal et al., “Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma,” The New England Journal of Medicine, vol. 357, no. 21, pp. 2123–2132, 2007. View at Publisher · View at Google Scholar · View at Scopus
  4. D. M. Weber, C. Chen, R. Niesvizky et al., “Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America,” The New England Journal of Medicine, vol. 357, no. 21, pp. 2133–2142, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Cavo, E. Zamagni, P. Tosi et al., “Superiority of thalidomide and dexamethasone over vincristine-doxorubicin- dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma,” Blood, vol. 106, no. 1, pp. 35–39, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. J. A. Zonder, J. Crowley, M. A. Hussein et al., “Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a randomized Southwest Oncology Group trial (S0232),” Blood, vol. 116, no. 26, pp. 5838–5841, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. S. V. Rajkumar, S. R. Hayman, M. Q. Lacy et al., “Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma,” Blood, vol. 106, no. 13, pp. 4050–4053, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. S. V. Rajkumar, L. Rosiñol, M. Hussein et al., “Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma,” Journal of Clinical Oncology, vol. 26, no. 13, pp. 2171–2177, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. S. V. Rajkumar, S. Jacobus, N. S. Callander et al., “Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial,” The Lancet Oncology, vol. 11, no. 1, pp. 29–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  10. R. Niesvizky, D. S. Jayabalan, P. J. Christos et al., “BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma,” Blood, vol. 111, no. 3, pp. 1101–1109, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. P. G. Richardson, E. Weller, S. Lonial et al., “Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma,” Blood, vol. 116, no. 5, pp. 679–686, 2010. View at Publisher · View at Google Scholar · View at Scopus
  12. S. K. Kumar, M. Q. Lacy, S. R. Hayman et al., “Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial,” American Journal of Hematology, vol. 86, no. 8, pp. 640–645, 2011. View at Publisher · View at Google Scholar · View at Scopus
  13. S. K. Kumar, I. Flinn, S. J. Noga et al., “Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study,” Leukemia, vol. 24, no. 7, pp. 1350–1356, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. A. J. Jakubowiak, K. A. Griffith, D. E. Reece et al., “Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 multiple myeloma research consortium trial,” Blood, vol. 118, no. 3, pp. 535–543, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. A. J. Jakubowiak, D. Dytfeld, S. Jagannath et al., “Final results of a frontline phase 1/2 study of carfilzomib, lenalidomide, and low-dose dexamethasone (CRd) in multiple myeloma (MM),” in Proceedings of the ASH Annual Meeting Abstracts, vol. 118, p. 631, December 2011.
  16. M. Coleman, J. Leonard, L. Lyons et al., “BLT-D (clarithromycin [Biaxin], low-dose thalidomide, and dexamethasone) for the treatment of myeloma and Waldenström's macroglobulinemia,” Leukemia and Lymphoma, vol. 43, no. 9, pp. 1777–1782, 2002. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Gay, S. V. Rajkumar, M. Coleman et al., “Clarithromycin (Biaxin)-lenalidomide-low-dose dexamethasone (BiRd) versus lenalidomide-low-dose dexamethasone (Rd) for newly diagnosed myeloma,” American Journal of Hematology, vol. 85, no. 9, pp. 664–669, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Kumar, I. W. Flinn, P. G. Richardson et al., “Novel three- and four-drug combination regimens of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide, for previously untreated multiple myeloma: results from the multi-center, randomized, phase 2 EVOLUTION study,” in Proceedings of the ASH Annual Meeting Abstracts, vol. 116, p. 621, December 2010.
  19. S. Kumar, A. Dispenzieri, M. Q. Lacy et al., “Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma,” Leukemia, vol. 21, no. 9, pp. 2035–2042, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Mark, J. Stern, J. R. Furst et al., “Stem cell mobilization with cyclophosphamide overcomes the suppressive effect of lenalidomide therapy on stem cell collection in multiple myeloma,” Biology of Blood and Marrow Transplantation, vol. 14, no. 7, pp. 795–798, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Mazumder, J. Kaufman, R. Niesvizky, S. Lonial, D. Vesole, and S. Jagannath, “Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients,” Leukemia, vol. 22, no. 6, pp. 1280–1281, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. I. N. M. Micallef, A. D. Ho, L. M. Klein, S. Marulkar, P. J. Gandhi, and P. A. McSweeney, “Plerixafor (Mozobil) for stem cell mobilization in patients with multiple myeloma previously treated with lenalidomide,” Bone Marrow Transplantation, vol. 46, no. 3, pp. 350–355, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. S. V. Rajkumar, G. Gahrton, and P. L. Bergsagel, “Approach to the treatment of multiple myeloma: a clash of philosophies,” Blood, vol. 118, pp. 3205–3211, 2011. View at Google Scholar
  24. J. L. Harousseau, M. Attal, and H. Avet-Loiseau, “The role of complete response in multiple myeloma,” Blood, vol. 114, no. 15, pp. 3139–3146, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Nooka, J. Kaufman, and S. Lonial, “The importance of complete response in outcomes in myeloma,” Cancer Journal, vol. 15, no. 6, pp. 465–472, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. M. Cavo, P. Tacchetti, F. Patriarca et al., “Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study,” The Lancet, vol. 376, no. 9758, pp. 2075–2085, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. Palumbo, “Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients,” Journal of Clinical Oncology, vol. 28, no. 5, pp. 800–807, 2010. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Wheatley, “Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients,” British Journal of Haematology, vol. 113, no. 4, pp. 1020–1034, 2001. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Attal, J. L. Harousseau, S. Leyvraz et al., “Maintenance therapy with thalidomide improves survival in patients with multiple myeloma,” Blood, vol. 108, no. 10, pp. 3289–3294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  30. H. M. Lokhorst, B. Van Der Holt, S. Zweegman et al., “A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma,” Blood, vol. 115, no. 6, pp. 1113–1120, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. Spencer, H. M. Prince, A. W. Roberts et al., “Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure,” Journal of Clinical Oncology, vol. 27, no. 11, pp. 1788–1793, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. P. L. McCarthy, K. Owzar, K. C. Anderson et al., “Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous hematopoietic stem cell transplantation (AHSCT) for multiple myeloma: CALGB 100104,” in Proceedings of the ASH Annual Meeting Abstracts, vol. 116, p. 37, December 2010.
  33. P. L. McCarthy, K. Owzar, K. C. Anderson et al., “Phase III Intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB ECOG BMT-CTN 100104,” Haematologica, vol. 96, p. S23, 2011. View at Google Scholar
  34. M. Attal, P. Olivier, C. V. Lauers et al., “Maintenance treatment with lenalidomide after transplantation for myeloma: analysis of secondary malignancies within the IFM 2005-02 trial,” Haematologica, vol. 96, p. S23, 2011. View at Google Scholar
  35. M. A. Dimopoulos, R. Z. Orlowski, R. Niesvizky et al., “Lenalidomide and dexamethasone (LEN plus DEX) treatment in relapsed/refractory multiple myeloma (RRMM) patients (pts) and risk of second primary malignancies (SPM): analysis of MM-009/010,” in Proceedings of the ASCO Meeting Abstracts, vol. 29, p. 8009, Chicago, Ill, USA, June 2011.
  36. A. P. Palumbo, M. Delforge, J. Catalano et al., “Incidence of second primary malignancy (SPM) in melphalan-prednisone-lenalidomide combination followed by lenalidomide maintenance (MPR-R) in newly diagnosed multiple myeloma patients (pts) age 65 or older,” in Proceedings of the ASCO Meeting Abstracts, vol. 29, p. 8007, Chicago, Ill, USA, June 2011.
  37. H. Avet-Loiseau, X. Leleu, M. Roussel et al., “Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p),” Journal of Clinical Oncology, vol. 28, no. 30, pp. 4630–4634, 2010. View at Publisher · View at Google Scholar · View at Scopus
  38. K. Neben, H. M. Lokhorst, A. Jauch et al., “Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p,” Blood, vol. 119, no. 4, pp. 940–948, 2012. View at Google Scholar